AIkido Pharma, Inc. (AIKI)

NASDAQ: AIKI · IEX Real-Time Price · USD
3.43
-0.11 (-3.11%)
Dec 5, 2022 4:00 PM EST - Market closed
-3.11%
Market Cap 19.42M
Revenue (ttm) n/a
Net Income (ttm) -20.77M
Shares Out 5.34M
EPS (ttm) -1.85
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date Jun 7, 2022
Volume 10,940
Open 3.54
Previous Close 3.54
Day's Range 3.4 - 3.54
52-Week Range 3.36 - 12.58
Beta 1.06
Analysts Buy
Price Target 16.32 (+375.8%)
Earnings Date Nov 9, 2022

About AIKI

AIkido Pharma Inc., a biotechnology company, focuses on developing small-molecule anti-cancer therapeutics. The company's pipeline of therapeutics includes therapies for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia. It is developing DHA-dFdC, a pancreatic drug candidate; and KPC34, a small molecule treatment for acute myeloid leukemia and acute lymphoblastic leukemia. The company is also developing an antiviral platform that inhibits replication of viruses, including influenza virus, Ebolavi... [Read more]

Industry Biotechnology
Founded 1967
CEO Anthony Hayes
Employees 4
Stock Exchange NASDAQ
Ticker Symbol AIKI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for AIKI stock is "Buy." The 12-month stock price forecast is 16.32, which is an increase of 375.80% from the latest price.

Price Target
$16.32
(375.80% upside)
Analyst Consensus: Buy
Stock Forecasts

News

AIkido Pharma Announces Successful Initial Public Offering of ASP Isotopes

Leading Advanced Materials Company Now Listed on NASDAQ under the symbol, ASPI NEW YORK , Nov. 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today announced the ...

1 week ago - PRNewsWire

AIkido Share Repurchase Continues

NEW YORK , Oct. 6, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") ...

1 month ago - PRNewsWire

AIkido Purchases More Shares

NEW YORK , Oct. 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") ...

2 months ago - PRNewsWire

Share Repurchase Program Continues

NEW YORK , Oct. 4, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the Company's share repurchase program (the "Share Repurchase Program") ...

2 months ago - PRNewsWire

AIkido Pharma Continues Share Repurchase Program

NEW YORK , Oct. 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program")...

2 months ago - PRNewsWire

AIkido Pharma Provides Update on Share Repurchase Program

NEW YORK , Sept. 30, 2022 /PRNewswire/ -- AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company") today provided an update on the $3 million share repurchase program (the "Share Repurchase Program...

2 months ago - PRNewsWire

Dominari Financial, Inc. Executes Definitive Agreement to Buy Broker-Dealer

Acquisition Will Accelerate Growth Strategy NEW YORK , Sept. 9, 2022 /PRNewswire/ -- Dominari Financial, Inc., the financial services subsidiary of AIkido Pharma Inc., (NASDAQ: AIKI) has entered into an...

2 months ago - PRNewsWire

AIkido Pharma Confirms Receipt of Unsolicited Offer

NEW YORK , Aug. 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today confirms that on August 9, 2022, the Company received an unsolicited offer from Mr. Shalom Au...

3 months ago - PRNewsWire

AIkido Pharma, Inc. Hires Carlos Aldavero to Lead Financial Services Subsidiary

Morgan Stanley Executive Joins Dominari Financial, Inc. on July 22, 2022 NEW YORK , July 21, 2022 /PRNewswire/ -- Anthony Hayes, CEO of AIkido Pharma Inc. (NASDAQ: AIKI) ("AIkido" or the "Company"), ann...

4 months ago - PRNewsWire

AIkido Pharma Inc. Regains Compliance with NASDAQ Listing Requirements

NEW YORK , June 28, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that on June 23, 2022, the Company received a letter from the Listing Qualification...

5 months ago - PRNewsWire

AIkido Inc. Announces the Formation of a New Financial Services Subsidiary

Long-Range Strategy Seeks Diversification into Three Key Industries NEW YORK , June 24, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") announced the formation of a wh...

5 months ago - PRNewsWire

AIkido Pharma Inc. Appoints New Director, Soo Yu

New Director Supports NASDAQ Rule on Diversity NEW YORK , June 10, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the appointment of Ms. Soo Yu, as a ...

5 months ago - PRNewsWire

Why Is AIkido Pharma (AIKI) Stock Up 1,400%?

AIkido Pharma (AIKI) stock is skyrocketing on Tuesday but it's not due to any positive news from the biotechnology company. The post Why Is AIkido Pharma (AIKI) Stock Up 1,400%?

5 months ago - InvestorPlace

AIkido Pharma stock falls again after reverse stock split takes effect

Shares of AIkido Pharma Inc. slumped 11.3% to pace all the premarket decliners Tuesday, after the biotechnology company's 1-for-17 reverse stock split took effect.

5 months ago - Market Watch

AIkido Announces Reverse Stock Split

NEW YORK , June 3, 2022 /PRNewswire/ -- AIkido Pharma, Inc. (NASDAQ:AIKI), today announced that the Company's Board of Directors has approved a reverse stock split of its shares of common stock at a rat...

6 months ago - PRNewsWire

AIkido Pharma Announces Company Commitment to Board Diversity

NEW YORK, May 19, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced the Company's commitment to complying with the NASDAQ listing requirements on board d...

6 months ago - PRNewsWire

AIkido Pharma Secures Interest in Databricks Inc.

Data and AI Company and a Pioneer of the Cutting-Edge Database Architecture NEW YORK , May 12, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the...

6 months ago - PRNewsWire

AIkido Reports Slinger Bag Inc.'s Filing for Nasdaq Public Listing

Company's Flagship Product, The Slinger Bag, Top Rated Among 2022 Tennis Products NEW YORK , May 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today reported that...

7 months ago - PRNewsWire

Glass Lewis Proxy Paper Report Recommends "FOR" AIkido Pharma Inc. Proposed Reverse Stock Split

Analysis Firm Agrees that Reverse Split Is in the Best Interest of the Company NEW YORK , April 22, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today reported that...

7 months ago - PRNewsWire

AIkido Pharma Announces Strategic Investment in MasterClass

Masterclass Provides Members Access to Pre-Recorded Lectures by Top Experts NEW YORK , April 5, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that th...

8 months ago - PRNewsWire

Cedars-Sinai Medical Center and AIkido Pharma Inc. to Codevelop Novel Immuno-Oncology Cancer Treatment

NEW YORK, March 11, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company and Cedars-Sinai Medical Center have agreed under their Master Col...

8 months ago - PRNewsWire

Cedars-Sinai Medical Center and AIkido Pharma Inc. Enter Into Master Collaboration Agreement

NEW YORK, March 8, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that the Company has entered into a Master Collaboration Agreement (MCA) with Cedars...

8 months ago - PRNewsWire

AIkido Pharma Reports Improved Manufacturing Process and New United States Patent for Pancreatic Drug

NEW YORK , March 3, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today reported an improvement in the manufacturing process for its pancreatic cancer drug, DHA-dFdC...

9 months ago - PRNewsWire

AIkido Pharma Inc. Announces Closing of $22 Million Registered Direct Offering

NEW YORK, March 2, 2022 /PRNewswire/ -- AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company"), today announced the closing of its previously announced registered direct offering with certain ins...

9 months ago - PRNewsWire